Hirakawa, T.; Yamaguchi, K.; Funaishi, K.; Shimoji, K.; Sakamoto, S.; Horimasu, Y.; Masuda, T.; Nakashima, T.; Iwamoto, H.; Hamada, H.;
et al. Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer. Cancers 2025, 17, 572.
https://doi.org/10.3390/cancers17040572
AMA Style
Hirakawa T, Yamaguchi K, Funaishi K, Shimoji K, Sakamoto S, Horimasu Y, Masuda T, Nakashima T, Iwamoto H, Hamada H,
et al. Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer. Cancers. 2025; 17(4):572.
https://doi.org/10.3390/cancers17040572
Chicago/Turabian Style
Hirakawa, Tetsu, Kakuhiro Yamaguchi, Kunihiko Funaishi, Kiyofumi Shimoji, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada,
and et al. 2025. "Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer" Cancers 17, no. 4: 572.
https://doi.org/10.3390/cancers17040572
APA Style
Hirakawa, T., Yamaguchi, K., Funaishi, K., Shimoji, K., Sakamoto, S., Horimasu, Y., Masuda, T., Nakashima, T., Iwamoto, H., Hamada, H., Yamada, S., & Hattori, N.
(2025). Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer. Cancers, 17(4), 572.
https://doi.org/10.3390/cancers17040572
